Qiagen N.V. is rated a Buy due to new product launches like QIAspirant Connect and strategic partnerships with Inpeco/Diasorin and NVIDIA AI, which are expected to drive revenue growth and offset weak demand for QuantiFERON. Management projects 1–2% constant exchange rate sales growth for fiscal year 2026, supported by early orders and broad market access in sample preparation. Despite trading at a discount to peers on price-to-sales multiples, Qiagen shows higher forward growth potential, suggesting positive momentum for investors.
Ethereum has recently outperformed Bitcoin, supported by strong ETF inflows exceeding $128 million and growing on-chain activity, particularly through Robinhood's new Layer 2 chain that uses ETH as its native gas token. This Layer 2 ecosystem has see...
BNB Chain remains the top blockchain by monthly active stablecoin addresses, hosting about 15 million users, surpassing rivals like Ethereum and Solana. This high user activity indicates strong retail participation and network utility, driven by BNB ...
BYD Company Limited showed robust export volumes and potentially higher average selling prices in Q2 2026, supporting improved financial results. Despite fierce competition in China, BYD remains the market leader and is poised to benefit from sustain...
Brian Armstrong, CEO of Coinbase, has proposed using Bitcoin as a "hard-backed currency" to address the United States' $39 trillion national debt. He suggests constitutional reforms and leveraging technologies like AI and cryptocurrencies to drive ec...
In June 2026, Bitfufu produced 125 BTC, down from May's daily average of 5.7 BTC to 4.2 BTC, due to a decrease in total power capacity from 346 MW to 273 MW. Despite this, the company's self-mined hashrate grew by 9.4% to 3.5 EH/s following new equip...
